

Dany Anglicheau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/379699/publications.pdf>

Version: 2024-02-01

133
papers

7,695
citations

61984

43
h-index

56724

83
g-index

143
all docs

143
docs citations

143
times ranked

8857
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of kidney-transplanted patients with history of intestinal reconstruction of the urinary tract. <i>BJUI Compass</i> , 2022, 3, 75-85.	1.3	2
2	Cell stress response impairs de novo NAD ⁺ biosynthesis in the kidney. <i>JCI Insight</i> , 2022, 7, .	5.0	23
3	Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial. <i>American Journal of Transplantation</i> , 2022, 22, 1430-1441.	4.7	5
4	Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab. <i>American Journal of Transplantation</i> , 2022, 22, 2099-2103.	4.7	14
5	The sexual dimorphism of kidney growth in mice and humans. <i>Kidney International</i> , 2022, 102, 78-95.	5.2	10
6	Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms. <i>Frontiers in Immunology</i> , 2022, 13, 864730.	4.8	11
7	Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection. <i>Kidney International</i> , 2022, 101, 1290-1293.	5.2	25
8	Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial. <i>Transplantation Direct</i> , 2022, 8, e1316.	1.6	7
9	FC 114: Monoclonal Gammopathy in Kidney Transplanted Patients: Novel Insights into Long-Term Outcomes. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
10	FC 117: Clinical Validation of Automated Urinary Chemokine Assays for Non-Invasive Detection of Kidney Transplant Rejection: A Large Prospective Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
11	Biological pathways and comparison with biopsy signals and cellular origin of peripheral blood transcriptomic profiles during kidney allograft pathology. <i>Kidney International</i> , 2022, 102, 183-195.	5.2	9
12	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	7.1	110
13	Diagnostic performance of kSORT, a blood-based mRNA assay for noninvasive detection of rejection after kidney transplantation: A retrospective multicenter cohort study. <i>American Journal of Transplantation</i> , 2021, 21, 740-750.	4.7	22
14	COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. <i>American Journal of Transplantation</i> , 2021, 21, 1285-1294.	4.7	69
15	Is COVID-19 infection more severe in kidney transplant recipients?. <i>American Journal of Transplantation</i> , 2021, 21, 1295-1303.	4.7	190
16	Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. <i>American Journal of Transplantation</i> , 2021, 21, 2448-2458.	4.7	31
17	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. <i>American Journal of Transplantation</i> , 2021, 21, 3021-3033.	4.7	8
18	Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. <i>Kidney International</i> , 2021, 99, 486-488.	5.2	30

#	ARTICLE	IF	CITATIONS
19	Ig-responsive relapsing inflammatory syndrome following COVID-19 in a kidney transplant recipient. <i>Kidney International</i> , 2021, 99, 767-768.	5.2	3
20	Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. <i>Transplantation</i> , 2021, 105, e94-e95.	1.0	105
21	A kidney discard decision strategy based on zero-time histology analysis could lead to an unjustified increase in the organ turndown rate among ECD. <i>Transplant International</i> , 2021, 34, 1506-1516.	1.6	1
22	Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2689-2693.	0.8	8
23	Impact of Covid-19 on kidney transplant and waiting list patients: Lessons from the first wave of the pandemic. <i>Nephrologie Et Therapeutique</i> , 2021, 17, 245-251.	0.5	8
24	Epidemiological and clinical study of microsporidiosis in French kidney transplant recipients from 2005 to 2019: TRANSPORE registry. <i>Transplant Infectious Disease</i> , 2021, 23, e13708.	1.7	5
25	The Case Cardiac tamponade in a kidney transplant recipient with chronic inflammation. <i>Kidney International</i> , 2021, 100, 487-488.	5.2	0
26	Occurrence of severe COVID-19 in vaccinated transplant patients. <i>Kidney International</i> , 2021, 100, 477-479.	5.2	101
27	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	11.9	357
28	Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. <i>American Journal of Transplantation</i> , 2021, 21, 4043-4051.	4.7	84
29	Immune Checkpoint Inhibitors in Transplantation—A Case Series and Comprehensive Review of Current Knowledge. <i>Transplantation</i> , 2021, 105, 67-78.	1.0	21
30	Integrative Omics Analysis Unravels Microvascular Inflammation-Related Pathways in Kidney Allograft Biopsies. <i>Frontiers in Immunology</i> , 2021, 12, 738795.	4.8	8
31	MicroRNAs: small molecules, big effects. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 10-16.	1.6	9
32	Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction. <i>Nature Communications</i> , 2021, 12, 6446.	12.8	35
33	CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3231-3251.	6.1	8
34	Belatacept as maintenance therapy in kidney transplant recipients with ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 194-195.	0.8	0
35	Belatacept as maintenance therapy in kidney transplant recipients with ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 194-195.	0.8	2
36	Central nervous system complications in adult cystinosis patients. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 348-356.	3.6	14

#	ARTICLE	IF	CITATIONS
37	Diagnostic yield of 18F-FDG PET/CT imaging and urinary CXCL9/creatinine levels in kidney allograft subclinical rejection. <i>American Journal of Transplantation</i> , 2020, 20, 1402-1409.	4.7	9
38	In situ multiplex immunofluorescence analysis of the inflammatory burden in kidney allograft rejection: A new tool to characterize the alloimmune response. <i>American Journal of Transplantation</i> , 2020, 20, 942-953.	4.7	36
39	Urinary Protein Biomarker Panel for the Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2020, 5, 1448-1458.	0.8	26
40	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. <i>Transplantation</i> , 2020, 104, 2625-2631.	1.0	15
41	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. <i>Kidney International</i> , 2020, 98, 1549-1558.	5.2	213
42	Deciphering the Prognostic and Predictive Value of Urinary CXCL10 in Kidney Recipients With BK Virus Reactivation. <i>Frontiers in Immunology</i> , 2020, 11, 604353.	4.8	9
43	IMPact of the COVID-19 epidemic on the moRTality of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). <i>Kidney International</i> , 2020, 98, 1568-1577.	5.2	85
44	Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2168-2183.	6.1	60
45	Antibody-mediated rejection with and without donor-specific anti-human leucocyte antigen antibodies: performance of the peripheral blood 8-gene expression assay. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1328-1337.	0.7	6
46	Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 3462-3476.	4.7	38
47	AA amyloidosis revealing mevalonate kinase deficiency: A report of 20 cases including two new French cases and a comprehensive review of literature. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1370-1373.	3.4	13
48	An extension of the RITUXA€ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. <i>Transplant International</i> , 2020, 33, 786-795.	1.6	18
49	1-Methyluric Acid Nephropathy. <i>Kidney International Reports</i> , 2020, 5, 737-741.	0.8	9
50	No impact of disseminated intravascular coagulation in kidney donors on long-term kidney transplantation outcome: A multicenter propensity-matched study. <i>American Journal of Transplantation</i> , 2019, 19, 448-456.	4.7	5
51	Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. <i>EBioMedicine</i> , 2019, 46, 463-472.	6.1	75
52	Survival and specific outcome of sickle cell disease patients after renal transplantation. <i>British Journal of Haematology</i> , 2019, 187, 676-680.	2.5	15
53	MicroRNA-146a-deficient mice develop immune complex glomerulonephritis. <i>Scientific Reports</i> , 2019, 9, 15597.	3.3	10
54	Acute kidney injury during an ultra-distance race. <i>PLoS ONE</i> , 2019, 14, e0222544.	2.5	12

#	ARTICLE	IF	CITATIONS
55	Osmoregulation Performance and Kidney Transplant Outcome. Journal of the American Society of Nephrology: JASN, 2019, 30, 1282-1293.	6.1	6
56	Sensitization to endothelial cell antigens: Unraveling the cause or effect paradox. Human Immunology, 2019, 80, 614-620.	2.4	18
57	Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. Kidney International, 2019, 95, 1471-1485.	5.2	40
58	Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens. Journal of the American Society of Nephrology: JASN, 2019, 30, 692-709.	6.1	81
59	Transplant center characteristics associated with living donor kidney transplantation: a cohort study with a hierarchical modeling approach. Transplant International, 2019, 32, 865-875.	1.6	1
60	Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. Transplantation, 2019, 103, 2150-2156.	1.0	18
61	No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained <scp>BK</scp> virus viremia after kidney transplantation: a single-center experience. Transplant International, 2019, 32, 481-492.	1.6	8
62	Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. Kidney International, 2019, 95, 188-198.	5.2	116
63	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. Nephrology Dialysis Transplantation, 2019, 34, 1597-1604.	0.7	2
64	Acute kidney injury during an ultra-distance race. , 2019, 14, e0222544.		0
65	Acute kidney injury during an ultra-distance race. , 2019, 14, e0222544.		0
66	Acute kidney injury during an ultra-distance race. , 2019, 14, e0222544.		0
67	Acute kidney injury during an ultra-distance race. , 2019, 14, e0222544.		0
68	Acute kidney injury during an ultra-distance race. , 2019, 14, e0222544.		0
69	Acute kidney injury during an ultra-distance race. , 2019, 14, e0222544.		0
70	Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. Transplant Infectious Disease, 2018, 20, e12846.	1.7	7
71	A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen. American Journal of Transplantation, 2018, 18, 2905-2913.	4.7	12
72	Post-Transplant Natural Antibodies Associate with Kidney Allograft Injury and Reduced Long-Term Survival. Journal of the American Society of Nephrology: JASN, 2018, 29, 1761-1770.	6.1	36

#	ARTICLE	IF	CITATIONS
73	Precision Transplant Medicine: Biomarkers to the Rescue. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 24-34.	6.1	74
74	Severe dermatophytosis in solid organ transplant recipients: A French retrospective series and literature review. <i>Transplant Infectious Disease</i> , 2018, 20, e12799.	1.7	44
75	Recurrence of Renal Cell Cancer After Renal Transplantation in a Multicenter French Cohort. <i>Transplantation</i> , 2018, 102, 860-867.	1.0	18
76	Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation. <i>Transplantation</i> , 2018, 102, 688-698.	1.0	31
77	Urinary transcriptomics reveals patterns associated with subclinical injury of the renal allograft. <i>Biomarkers in Medicine</i> , 2018, 12, 427-438.	1.4	3
78	Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. <i>Kidney International</i> , 2018, 94, 964-973.	5.2	198
79	The 1-year Renal Biopsy Index: a scoring system to drive biopsy indication at 1-year post-kidney transplantation. <i>Transplant International</i> , 2018, 31, 947-955.	1.6	5
80	Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes. <i>Transplantation</i> , 2017, 101, 649-656.	1.0	59
81	Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA. <i>Transplantation</i> , 2017, 101, 2440-2448.	1.0	60
82	Clinical impact of the <i>CYP3A5</i> 6986A>G allelic variant on kidney transplantation outcomes. <i>Pharmacogenomics</i> , 2017, 18, 165-173.	1.3	16
83	A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1663-1670.	4.5	32
84	The Association Between Fibroblast Growth Factor-23 and Renal Transplantation Outcome Is Modified by Follow-up Duration and Glomerular Filtration Rate Assessment Method. <i>Kidney International Reports</i> , 2017, 2, 881-892.	0.8	9
85	Lung cancer in renal transplant recipients: A case-control study. <i>Lung Cancer</i> , 2017, 111, 96-100.	2.0	10
86	MicroRNA-146a in Human and Experimental Ischemic AKI: CXCL8-Dependent Mechanism of Action. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 479-493.	6.1	81
87	A Comparative Study of the Predictive Values of Urinary Acute Kidney Injury Markers Angiogenin and Kidney Injury Molecule 1 for the Outcomes of Kidney Allografts. <i>Transplantation Direct</i> , 2017, 3, e204.	1.6	5
88	Establishing Biomarkers in Transplant Medicine. <i>Transplantation</i> , 2016, 100, 2024-2038.	1.0	71
89	Stat3 Controls Tubulointerstitial Communication during CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3690-3705.	6.1	75
90	Ultrasound-based imaging methods of the kidney—recent developments. <i>Kidney International</i> , 2016, 90, 1199-1210.	5.2	63

#	ARTICLE	IF	CITATIONS
91	Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study. <i>Transplant International</i> , 2016, 29, 1205-1215.	1.6	7
92	Pathogenesis of non-HLA antibodies in solid organ transplantation: Where do we stand?. <i>Human Immunology</i> , 2016, 77, 1055-1062.	2.4	26
93	A Novel Extrinsic Pathway for the Unfolded Protein Response in the Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2670-2683.	6.1	26
94	Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 487-495.	0.7	23
95	De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection. <i>Transplantation</i> , 2015, 99, 965-972.	1.0	28
96	Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2840-2851.	6.1	112
97	A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. <i>Science Translational Medicine</i> , 2014, 6, 256ra136.	12.4	172
98	At the End of the Day, Should We Consider Chronic Histological Lesions?. <i>Transplantation</i> , 2014, 98, 382-383.	1.0	0
99	MicroRNAs as biomarkers of graft outcome. <i>Transplantation Reviews</i> , 2014, 28, 111-118.	2.9	29
100	The Kidney as a Reservoir for HIV-1 after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 407-419.	6.1	121
101	Antibody-mediated vascular rejection of kidney allografts: a population-based study. <i>Lancet, The</i> , 2013, 381, 313-319.	13.7	308
102	Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 471-478.	0.7	18
103	Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival. <i>New England Journal of Medicine</i> , 2013, 369, 1215-1226.	27.0	746
104	Vitamin D Status and Outcomes After Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 831-841.	6.1	93
105	Discovery and Validation of a Molecular Signature for the Noninvasive Diagnosis of Human Renal Allograft Fibrosis. <i>Transplantation</i> , 2012, 93, 1136-1146.	1.0	35
106	Clinical and immunological features of very long-term survivors with a single renal transplant. <i>Transplant International</i> , 2012, 25, 545-554.	1.6	26
107	Impact of Norovirus/Sapovirus-Related Diarrhea in Renal Transplant Recipients Hospitalized for Diarrhea. <i>Transplantation</i> , 2011, 92, 61-69.	1.0	130
108	Donor-Specific Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 975-983.	6.1	88

#	ARTICLE	IF	CITATIONS
109	Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study. <i>Transplantation</i> , 2010, 89, 1403-1410.	1.0	133
110	Cidofovir May Be Deleterious in BK Virus-Associated Nephropathy. <i>Transplantation</i> , 2010, 89, 1542-1544.	1.0	19
111	Glomerular Collapse Associated With Subtotal Renal Infarction in Kidney Transplant Recipients With Multiple Renal Arteries. <i>American Journal of Kidney Diseases</i> , 2010, 55, 558-565.	1.9	22
112	MicroRNA expression profiles predictive of human renal allograft status. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5330-5335.	7.1	312
113	Endoplasmic Reticulum Stress: An Unrecognized Actor in Solid Organ Transplantation. <i>Transplantation</i> , 2009, 88, 605-613.	1.0	41
114	Response of human renal tubular cells to cyclosporine and sirolimus: A toxicogenomic study. <i>Toxicology and Applied Pharmacology</i> , 2008, 229, 184-196.	2.8	51
115	Early Epithelial Phenotypic Changes Predict Graft Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1584-1591.	6.1	121
116	High-Dosage Intravenous Immunoglobulin-Associated Macrovacuoles Are Associated with Chronic Tubulointerstitial Lesion Worsening in Renal Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1461-1468.	4.5	14
117	Autophagy protects renal tubular cells against cyclosporine toxicity. <i>Autophagy</i> , 2008, 4, 783-791.	9.1	158
118	Role of Pharmacogenetics of Immunosuppressive Drugs in Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 143-150.	2.0	55
119	Long-term outcome of third kidney transplants. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2693-2700.	0.7	34
120	Impact of Surgical Procedures and Complications on Outcomes of Third and Subsequent Kidney Transplants. <i>Transplantation</i> , 2007, 83, 385-391.	1.0	29
121	Cytochrome P450 <i>CYP3A</i> polymorphisms and immunosuppressive drugs: an update. <i>Pharmacogenomics</i> , 2007, 8, 835-849.	1.3	91
122	Comparison of Sequential Protocol using Basiliximab versus Antithymocyte Globulin with High-Dose Mycophenolate Mofetil in Recipients of a Kidney Graft from an Expanded-Criteria Donor. <i>Transplantation</i> , 2006, 81, 949-952.	1.0	13
123	Sirolimus Early Graft Nephrotoxicity: Clinical and Experimental Data. <i>Current Drug Safety</i> , 2006, 1, 179-187.	0.6	13
124	Rapamycin inhibits human renal epithelial cell proliferation: Effect on cyclin D3 mRNA expression and stability. <i>Kidney International</i> , 2005, 67, 2422-2433.	5.2	58
125	Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy. <i>American Journal of Transplantation</i> , 2005, 5, 595-603.	4.7	129
126	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 422-433.	4.7	171

#	ARTICLE	IF	CITATIONS
127	Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2409-2414.	0.7	149
128	Octogenarians Reaching End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1012-1021.	6.1	278
129	Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1889-1896.	6.1	257
130	Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. <i>Transplantation</i> , 2003, 76, 1233-1235.	1.0	257
131	Thiopurine methyltransferase activity: new conditions for reversed-phase high-performance liquid chromatographic assay without extraction and genotypic phenotypic correlation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 773, 119-127.	2.3	32
132	Recent issues concerning renal transplantation in systemic lupus erythematosus patients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 12-14.	0.7	27
133	Long-Term Results of TPMT Activity Monitoring in Azathioprine-Treated Renal Allograft Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 170-176.	6.1	35